abp stock: Abpro Holdings, Inc. Overview

Abpro Holdings, Inc. (ABP)

abp stock refers to Abpro Holdings, Inc., which trades on the NASDAQ under the ticker ABP and is commonly classified as a microcap or penny stock. As of January 28, 2026, abp stock is a small‑market‑capitalization biotechnology equity focused on multispecific antibody therapeutics for oncology and ophthalmology, with lead candidates such as ABP‑102 among programs in development. This article explains Abpro’s business, corporate history, pipeline, collaborations, trading profile, recent news, regulatory and governance items, and investment considerations for readers seeking a factual, reference‑style summary.

Quick reader note: This article is informational and cites public aggregators and company disclosures. It is not investment advice. For primary documents, consult company press releases and SEC filings.

Company overview

Abpro Holdings, Inc. is a clinical‑stage biotechnology company developing multispecific antibody therapeutics. The company’s technology platforms include DiversImmune and MultiMab, which are designed to create multispecific antibodies that engage multiple targets simultaneously — a strategy intended to improve potency, selectivity, and therapeutic window in immune‑oncology and ocular vascular disease.

• Primary therapeutic focus: immuno‑oncology (solid tumors) and ocular vascular disease (retinal neovascular and vascular leakage disorders).
• Key technology platforms: DiversImmune (diversified immune‑repertoire discovery and optimization) and MultiMab (engineering multispecific antibody constructs, including bispecific and T‑cell engager formats).
• Headquartered in Woburn, Massachusetts, United States.
• Corporate model: in‑house R&D supported by partnerships and outsourced manufacturing relationships; advancement of selected lead candidates into IND‑enabling studies and clinical trials.

Abpro operates as a small, publicly listed biotechnology company that transitioned to the public markets through a business combination. The company concentrates resources on a compact pipeline of multispecific candidates and relies on collaborations for development and manufacturing scale‑up.

Corporate history

Early history and corporate formation

Abpro originated as a private biotechnology company focused on antibody engineering and discovery. The firms that became Abpro built intellectual property around multispecific antibody formats and preclinical programs directed at oncology and ocular disease. Prior to listing, the company and/or its assets were associated with a special purpose acquisition company (SPAC) or business combination vehicle for the purpose of accessing public markets; public coverage of the company references such a transaction in its path to listing.

Business combination and public listing

Abpro became a publicly traded company through a business combination that resulted in its listing on the NASDAQ under the ticker ABP. Public coverage noted milestone events commonly associated with such transactions, including announcements of definitive agreements, shareholder communications, and eventual NASDAQ listing and bell‑ringing activities. As with many microcap biotech companies that access public markets via a business combination, Abpro’s public listing enabled access to capital markets while increasing reporting and compliance obligations.

Recent corporate events

As of January 28, 2026, public sources reported several material corporate developments for Abpro:

• Management changes: press reports and company disclosures have referenced departures and appointments among executive officers, including at times CEO or C‑suite transitions. These changes can be material for abp stock, given the company’s small size and concentrated leadership.
• NASDAQ communications: abp stock has been subject to Nasdaq deficiency notices and follow‑up correspondence in periods where filing deadlines or listing standards required remediation. Company filings and press releases have described steps taken to restore compliance or to seek cure periods.
• Other announcements: periodic corporate updates have included pipeline progress, data presentations at scientific meetings, and partnership agreements that affect development timelines.

(For exact dates and formal statements, consult Abpro’s SEC filings and company press releases. The summary above aggregates reported items from financial aggregators and database summaries.)

Research programs and product pipeline

Abpro’s pipeline centers on multispecific antibody constructs designed for oncology and ocular disease. Below is a concise catalog of lead and notable development candidates based on company disclosures and press releases.

• ABP‑102 — HER2 x CD3 T‑cell engager. A multispecific T‑cell engager designed to redirect T cells to HER2‑expressing tumor cells for treatment of HER2‑positive solid tumors. Intended mechanism: bispecific engagement of tumor antigen (HER2) and CD3 on T cells to effect cytotoxicity.
• ABP‑201 — VEGF/Ang‑2 (VEGF/ANG‑2 dual inhibitor) for retinal vascular disease. A multispecific antibody aimed at inhibiting vascular endothelial growth factor (VEGF) and angiopoietin‑2 (ANG‑2) to reduce neovascularization and vascular leakage in retinal diseases.
• ABP‑110 — Preclinical multispecific oncology candidate. Reported as a discovery‑stage multispecific antibody targeting tumor‑associated antigens with immune‑engagement features.
• ABP‑150 — Preclinical ocular or systemic candidate listed among discovery programs. Early stage with mechanism tailored to vascular regulation or immunomodulation.

Each candidate’s development status ranges from preclinical to IND‑enabling activities. Company press releases and presentations at scientific conferences have been used to disclose mechanism‑of‑action data and preclinical proof‑of‑concept results.

Collaborations and partnerships

Abpro has pursued strategic collaborations to support development and manufacturing. Public disclosures have cited partnerships to advance particular programs and to supply manufacturing scale and technical expertise.

• Development and manufacturing alliances: press releases reference contract manufacturing and development agreements to enable IND enabling studies and potential clinical supply.
• Strategic collaborations: company statements and aggregator reports have referenced collaborations with international biopharmaceutical partners to broaden development capabilities and potential commercialization channels.

Such alliances are typical for small biotechs: they allow access to specialized capabilities while conserving corporate cash for core R&D. The precise terms and stages of these collaborations are detailed in company announcements and SEC filings.

Stock and market information

Ticker and exchange

• Ticker symbol: ABP
• Exchange: NASDAQ
• Classification: widely reported as a microcap or penny stock due to low market capitalization and sub‑dollar to low‑dollar trading prices in recent periods.

When seeking to trade abp stock, investors and traders often consider the exchange, liquidity, and brokerage options. For users of Bitget products: Bitget provides tools for market monitoring and order execution; readers may explore Bitget's trading services and Bitget Wallet for custody where appropriate.

Trading characteristics

abp stock typically exhibits the following trading features, as reported by market aggregators:

• Market capitalization: as of January 28, 2026, public aggregators reported abp stock in the low tens of millions of dollars range. Reported estimates vary by source; several financial data sites categorize ABP as a microcap with market cap commonly reported between approximately $10 million and $50 million.
• Average daily trading volume: aggregated data showed 30‑day average volumes in the low hundreds of thousands of shares, with large day‑to‑day variability tied to news and corporate announcements.
• Float and outstanding shares: the company has a relatively small public float compared with larger biotech peers, which can accentuate price swings when institutional or retail flows change.
• Volatility and bid‑ask spreads: abp stock demonstrates typical penny‑stock traits — pronounced price volatility, potentially wide bid‑ask spreads, and low liquidity that can magnify percentage moves on modest net flows.

These trading characteristics are commonly reported by market‑data aggregators and brokerage quote pages. Exact numerical values and recent history should be checked on the date of interest via the company’s exchange quotes and filings.

Historical price highlights and analyst coverage

• Price movements: abp stock has experienced significant percentage declines from prior intraday or historical highs reported on some quote aggregators. Large declines are not uncommon for early‑stage biotech microcaps following dilution, negative trial news, or general market sentiment shifts.
• 52‑week range: aggregator pages have reported ABP’s 52‑week high and low values; readers should consult market quotes for the current range.
• Analyst coverage and price targets: coverage is limited. Some financial aggregators have recorded single‑analyst initiations or price targets (for example, an example price target of $4 has been cited in historical aggregator snapshots). Given limited coverage, consensus estimates may be sparse or unavailable.

Ownership and insider holdings

• Institutional vs. insider ownership: public data show that insider ownership and holdings by company officers and early stakeholders can be material for abp stock, often representing a meaningful portion of the total outstanding shares. Institutional ownership tends to be low relative to large‑cap biotech peers.
• Insider transactions: periodic insider buys or sells are disclosed in SEC forms and summarized by financial aggregators; such transactions can be informative but should be confirmed with primary filings.

Financials

Key financial metrics

Abpro is a research‑stage biotechnology company and, as reported in recent financial summaries, has the financial profile typical of small clinical‑stage biotechs:

• Revenue: nominal or very low trailing‑twelve‑month revenue, reflecting pre‑commercial status for lead candidates.
• Net loss: recurring operating losses driven by R&D and G&A expenses; negative EPS reported in recent fiscal periods.
• Cash position: cash and cash equivalents balances have been modest and disclosed in periodic filings. The company has historically required access to additional capital through equity financings, partnerships, or other financing mechanisms to fund development.

Exact figures (revenue, net loss, cash on hand) are reported in the company’s SEC filings (Form 10‑Q, 10‑K and related statements). Readers should consult the most recent filings for precise amounts and quarter‑by‑quarter trends.

Reporting and compliance history

Abpro has had periods of intensified reporting activity tied to SEC filings and Nasdaq compliance. Public sources have documented instances of delayed filings or Nasdaq deficiency notices; these events have required remediation steps such as filing overdue reports or providing Nasdaq with plans to cure deficiencies. Such compliance events are material and typically disclosed in company filings and press releases.

Corporate governance and management

Abpro’s governance structure follows standard public‑company frameworks:

• Board composition: a small board of directors including independent and non‑executive members; specific names and committee assignments are listed in proxy statements and SEC filings.
• Executive officers: CEO, CFO, and senior R&D leaders are publicly disclosed; however, recent reporting has noted changes to executive roles at times, which are material for abp stock.
• Governance practices: the company files standard public‑company disclosures, including annual reports and insider transaction reports, and maintains audit and compensation committees as required by listing rules and corporate governance norms.

When evaluating governance for abp stock, readers should check the latest proxy materials and SEC disclosures for up‑to‑date director biographies, related‑party transactions, and executive compensation.

Recent news and developments

Below is a factual summary of the types of recent developments that have been reported for Abpro and abp stock across financial aggregators and company communications. For each item, readers should consult the primary source for precise dates and wording.

• Data presentations: Abpro has presented preclinical data at scientific conferences (for example, AACR or similar meetings). These presentations describe preclinical efficacy, mechanism data, and plans for IND enabling studies.
• Regulatory filings and IND activity: public statements have described progress toward IND‑enabling studies for lead candidates, and in some cases announcements of IND submissions or anticipated regulatory milestones.
• Management changes and organizational updates: the company has disclosed executive departures and new appointments in press releases and SEC filings; such changes are notable given the small management team.
• Nasdaq compliance notices: the company has disclosed receipt of Nasdaq deficiency notices and subsequent remediation efforts or requests for cure periods.
• Partnership announcements: selective collaborations for development or manufacturing have been reported, which may affect timelines for moving candidates into clinical testing.

As of January 28, 2026, readers should verify the most current press releases and SEC filings for exact dates, statements, and regulatory status.

Risks and investment considerations

The following are principal risks associated with abp stock based on the company’s profile and public reportage. The list is factual in nature and does not constitute investment advice.

• Early‑stage clinical and regulatory risk: lead programs are preclinical or early clinical; success in IND enabling studies or clinical trials is uncertain.
• Small market capitalization and low liquidity: microcap status and small float can lead to sharp price volatility and difficulty executing large trades without market impact.
• Dilution risk: small biotechs frequently raise capital through equity issuance, which can dilute existing shareholders and affect abp stock price.
• Dependency on partnerships and third‑party manufacturers: delays or changes in collaboration agreements or manufacturing capabilities can slow development programs.
• Reporting and compliance risk: prior Nasdaq deficiency notices or delayed filings highlight a governance and compliance risk that investors should monitor.
• Limited analyst coverage: sparse sell‑side coverage can lead to less public information, wider information asymmetry, and more pronounced market reactions to company announcements.

Investors and readers should rely on primary filings and verified company disclosures when assessing these risks.

Regulatory and legal matters

Regulatory matters that affect Abpro’s programs include routine preclinical and clinical regulatory interactions such as IND submissions and biotech regulatory correspondence. Public reporting referenced IND‑enabling activities and regulatory milestone planning for lead candidates. Separately, the company’s listing on NASDAQ subjects it to exchange rules; public records have reported Nasdaq notifications related to filing compliance.

Material legal matters — such as litigation, major contractual disputes, or regulatory sanctions — would be disclosed in SEC filings and press releases. At times, public aggregators note compliance or filing issues, but readers should refer to the company’s official SEC disclosures for legally binding descriptions.

See also

• Multispecific antibodies
• T‑cell engagers
• SPAC business combinations
• Microcap stocks and penny stocks
• Strategic biopharma partnerships (contract development and manufacturing)

References and external links

Below are the principal public sources commonly used to compile financial‑market profiles for abp stock. For verification of price data, filings, and news, consult the company’s SEC filings and the listed aggregators' pages and press releases. The entries below are cited by source name and should be cross‑checked on the date of interest.

• Abpro Holdings, Inc. — company press releases and SEC filings (Form 10‑Q, 10‑K, 8‑K)
• MarketBeat — “Abpro (ABP) Stock Price, News & Analysis” (aggregator coverage)
• Business Insider / Markets Insider — “Abpro Holdings Stock Price | ABP Stock Quote, News, and History”
• Yahoo Finance — “Abpro Holdings, Inc. (ABP) Stock Price, News, Quote & History”
• TradingView — “ABP - Abpro Holdings, Inc.” quote and chart data
• FINVIZ — ticker snapshot and fundamentals
• Robinhood / Public.com — retail brokerage summary pages

Reported metrics and dates cited in this article are drawn from the above sources and from Abpro’s own disclosures. As of January 28, 2026, several aggregators reported abp stock market capitalization in the low tens of millions of dollars and 30‑day average volume in the low hundreds of thousands of shares; for precise, current numbers consult the official quotations and filings.

Notation of source reporting dates

• As of January 28, 2026, according to MarketBeat and Yahoo Finance aggregations, ABP was classified as a microcap with market capitalization reported in the low tens of millions of dollars and modest daily liquidity.
• As of January 28, 2026, Business Insider / Markets Insider and TradingView quote pages reflected limited analyst coverage and a wide 52‑week trading range consistent with small biopharma microcaps.

(For exact numerical values and time series data, consult the referenced sites and Abpro’s SEC filings for the most recent reporting period.)

Practical steps to follow abp stock and company filings

• Monitor Abpro’s SEC filings (Form 10‑Q, 10‑K, and 8‑K) for official financial statements, risk disclosures, and material event notifications.
• Track company press releases for pipeline milestones, IND submissions, data presentations, and partnership announcements.
• Follow market‑data aggregators and exchange quote pages for real‑time price and volume data; note that abp stock’s low float can produce rapid intraday moves.
• Review insider filing reports for insider transactions and changes in beneficial ownership.

Actionable tip for Bitget users: If you use Bitget for market monitoring, consider adding ABP to your watchlist and enable alerts for company press releases and regulatory filings. For custody and transfers, Bitget Wallet is recommended when using Bitget services.

Authoritative verification and primary sources

This article synthesizes information from public market aggregators and Abpro’s disclosures. For legal‑grade verification, consult primary sources directly:

• Abpro Holdings, Inc. — company investor relations and SEC filings (primary source for financial data and official announcements)
• SEC EDGAR — filings filed by Abpro Holdings, Inc.
• Scientific conference abstracts and presentation materials where Abpro reported preclinical data
• Market data snapshot pages maintained by MarketBeat, Yahoo Finance, TradingView, FINVIZ and retail broker pages (for price and volume snapshots)

Final notes and reading suggestions

abp stock is a microcap biotechnology security with development programs built on multispecific antibody technology. The company’s prospects depend on successful IND enabling studies, regulatory interactions, adequate financing, and operational execution. The small market capitalization and limited liquidity of abp stock create typical microcap dynamics: larger percentage price moves and sensitivity to news flow.

For readers wanting to follow abp stock more closely: prioritize primary documents (SEC filings and company press releases), monitor trading volume and float, and verify any material management or regulatory updates directly from Abpro’s official channels. If you use Bitget for market access, explore Bitget’s watchlist, alerts, and custody options via Bitget Wallet to stay updated on developments.

Reminder: This article is informational and neutral in tone. It does not constitute investment advice or a recommendation to buy or sell abp stock. Always consult licensed financial professionals and primary company filings when making investment decisions.